Английская Википедия:Clomipramine

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Use dmy dates Шаблон:Cs1 config Шаблон:Infobox drug Clomipramine, sold under the brand name Anafranil among others, is a tricyclic antidepressant (TCA).[1] It is used in the treatment of various conditions, most-notably obsessive–compulsive disorder but also many other disorders, including panic disorder, major depressive disorder, trichotilomania,[2] body dysmorphic disorder[3][4][5] and chronic pain.[1] It has also been notably used to treat premature ejaculation[1] and the cataplexy associated with narcolepsy.[6][7]

It may also address certain fundamental features surrounding narcolepsy besides cataplexy (especially hypnagogic and hypnopompic hallucinations).[8] The evidence behind this, however, is less robust.

As with other antidepressants (notably including selective serotonin reuptake inhibitors), it may paradoxically increase the risk of suicide in those under the age of 25, at least in the first few weeks of treatment.[1]

It is typically taken by mouth, although intravenous preparations are sometimes used.[9][10]

Common side effects include dry mouth, constipation, loss of appetite, sleepiness, weight gain, sexual dysfunction, and trouble urinating.[1] Serious side effects include an increased risk of suicidal behavior in those under the age of 25, seizures, mania, and liver problems.[1] If stopped suddenly, a withdrawal syndrome may occur with headaches, sweating, and dizziness.[1] It is unclear if it is safe for use in pregnancy.[1] Its mechanism of action is not entirely clear but is believed to involve increased levels of serotonin and norepinephrine.[1]

Clomipramine was discovered in 1964 by the Swiss drug manufacturer Ciba-Geigy.[11] It is on the World Health Organization's List of Essential Medicines.[12] It is available as a generic medication.[1] Шаблон:TOC limit

Medical uses

Clomipramine has a number of uses in medicine, including in the treatment of:

Although lithium is most-associated with the treatment of bipolar disorder (where it is known for its general mood-stabilising features and to be especially useful in treating and preventing mania), it may have a certain place in the management of treatment-resistant depression (which is often of higher severity than other depressions which have not been addressed with ECT). In these cases is often prescribed alongside SSRIs (e.g., fluoxetine, paroxetine), venlafaxine and various of the tricyclics (e.g., clomipramine, amitriptyline, nortriptyline, maprotiline), which is why it may feature sometimes in the discussion of depression being managed with clomipramine. Lithium also significantly reduces the long-term risk of suicide in general.[55][56][57] In any case, it is not necessary to have a diagnosis of bipolar affective disorder (manic-depressive illness), or even to be considered to have subtle elements of it (“soft bipolarity”), to benefit from lithium in the context of treatment with clomipramine.

In a meta-analysis of various trials involving fluoxetine (Prozac), fluvoxamine (Faverin/Luvox), and sertraline (Zoloft) to test their relative efficacies in treating OCD, clomipramine was found to be significantly more effective.[58][59]

Contraindications

Contraindications include:[16]

  • Known hypersensitivity to clomipramine, or any of the excipients or cross-sensitivity to tricyclic antidepressants of the dibenzazepine group
  • Recent myocardial infarction
  • Any degree of heart block or other cardiac arrhythmias
  • Mania
  • Severe liver disease
  • Narrow angle glaucoma
  • Untreated urinary retention
  • It must not be given in combination or within 3 weeks before or after treatment with a monoamine oxidase inhibitor. (Moclobemide included; however, clomipramine may be initiated sooner at 48 hours following discontinuation of moclobemide.)

Pregnancy and lactation

Clomipramine use during pregnancy is associated with congenital heart defects in the newborn.[18][60] It is also associated with reversible withdrawal effects in the newborn.[61] Clomipramine is also distributed in breast milk and hence nursing while taking clomipramine is advised against.[14]

Side effects

Clomipramine has been associated with the side effects listed below:[13][14][15][16]

Very common (>10% frequency): Шаблон:Div col

Шаблон:Div col end

Common (1–10% frequency): Шаблон:Div col

Шаблон:Div col end

Uncommon (0.1–1% frequency):

  • Convulsions
  • Ataxia
  • Arrhythmias
  • Elevated blood pressure
  • Activation of psychotic symptoms

Very rare (<0.01% frequency): Шаблон:Div col

  • Pancytopaenia — an abnormally low amount of all the different types of blood cells in the blood (including platelets, white blood cells and red blood cells).
  • Leukopenia — a low white blood cell count.
  • Agranulocytosis — a more severe form of leukopenia; a dangerously low neutrophil count which leaves one open to life-threatening infections due to the role of the white blood cells in defending the body from invaders.
  • Thrombocytopenia — an abnormally low amount of platelets in the blood which are essential to clotting and hence this leads to an increased tendency to bruise and bleed, including, potentially, internally.
  • Eosinophilia — an abnormally high number of eosinophils — the cells that fight off parasitic infections — in the blood.
  • Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) — a potentially fatal reaction to certain medications that is due to an excessive release of antidiuretic hormone — a hormone that prevents the production of urine by increasing the reabsorption of fluids in the kidney — this results in the development of various electrolyte abnormalities (e.g. hyponatraemia [low blood sodium], hypokalaemia [low blood potassium], hypocalcaemia [low blood calcium]).
  • Glaucoma
  • Oedema (local or generalised)
  • Alopecia (hair loss)
  • Hyperpyrexia (a high fever that is above 41.5 °C)
  • Hepatitis (liver swelling) with or without jaundice — the yellowing of the eyes, the skin, and mucous membranes due to impaired liver function.
  • Abnormal ECG
  • Anaphylactic and anaphylactoid reactions including hypotension
  • Neuroleptic malignant syndrome (NMS) — a potentially fatal side effect of antidopaminergic agents such as antipsychotics, tricyclic antidepressants and antiemetics (drugs that relieve nausea and vomiting). NMS develops over a period of days or weeks and is characterised by the following symptoms:
    • Tremor
    • Muscle rigidity
    • Mental status change (such as confusion, delirium, mania, hypomania, agitation, coma, etc.)
    • Hyperthermia (high body temperature)
    • Tachycardia (high heart rate)
    • Blood pressure changes
    • Diaphoresis (sweating profusely)
    • Diarrhoea
  • Alveolitis allergic (pneumonitis) with or without eosinophilia
  • Purpura

Шаблон:Div col end

Individual side-effects may or may not be amendable to treatment. As noted below, bethanechol may alleviate anti-muscarinic/anti-cholinergic side-effects. It may also treat sexual side-effects common to clomipramine and SSRIs.[62][63]

Topiramate has been used to off-set the weight-gain induced from various antidepressants and antipsychotics,[64] and more broadly for general weight-loss (likewise with bupropion).[64] This option may be especially attractive in patients either overweight prior to clomipramine treatment or who have gained an undesirable amount of weight on it, as the weight-loss associated with topiramate may be very impressive indeed.[65][66][67][68][69]

Another potential advantage of topiramate in the adjunctive treatment of people taking clomipramine is engendered in its status as an anti-convulsant medication, thereby theoretically increasing the seizure-threshold in patients (which clomipramine decreases to an extent which precludes its dosage ranging above 250 m.g./d. in normal circumstances, likewise with maprotiline and its 225 m.g./d. upper-ceiling). It may, thus, be useful and of increased importance in any case for patients with a familial or personal history of epilepsy or seizures of some other kind to concurrently take a daily dose of an anti-convulsant drug (topiramate, gabapentin, etc.) should they require or opt for treatment with an antidepressant which reduces the seizure-threshold significantly (bupropion, clomipramine, amoxapine, maprotiline, venlafaxine). In the case of seizures occurring due to overdose of tricyclic antidepressants, intravenous lorazepam may successfully abort them. Phenytoin may or may not prevent them in the first instance but its status as an appropriate acute treatment for these seizures is somewhat controversial.[70][71][72]

Tremor may be relieved with a beta-blocker (e.g., pindolol, propranolol, atenolol). In certain cases of tremor, pindolol may be an especially sensible option for serious consideration, as there is substantial evidence that its utilisation is an effective augmentation-strategy for obsessive-compulsive disorder, an important indication for clomipramine.[73][74][75][76][77]

Withdrawal

Withdrawal symptoms may occur during gradual or particularly abrupt withdrawal of tricyclic antidepressant drugs. Possible symptoms include: nausea, vomiting, abdominal pain, diarrhea, insomnia, headache, nervousness, anxiety, dizziness and worsening of psychiatric status.[15] Differentiating between the return of the original psychiatric disorder and clomipramine withdrawal symptoms is important.[78] Clomipramine withdrawal can be severe.[79] Withdrawal symptoms can also occur in neonates when clomipramine is used during pregnancy.[61] A major mechanism of withdrawal from tricyclic antidepressants is believed to be due to a rebound effect of excessive cholinergic activity due to neuroadaptations as a result of chronic inhibition of cholinergic receptors by tricyclic antidepressants. Restarting the antidepressant and slow tapering is the treatment of choice for tricyclic antidepressant withdrawal. Some withdrawal symptoms may respond to anticholinergics, such as atropine or benztropine mesylate.[80]

Overdose

Шаблон:Main

Clomipramine overdose usually presents with the following symptoms:[13][15][16] Шаблон:Div col

  • Signs of central nervous system depression such as:
    • stupor
    • coma
    • drowsiness
    • restlessness
    • ataxia
  • Mydriasis
  • Convulsions
  • Enhanced reflexes
  • Muscle rigidity
  • Athetoid and choreoathetoid movements
  • Serotonin syndrome - a condition with many of the same symptoms as neuroleptic malignant syndrome but has a significantly more rapid onset
  • Cardiovascular effects including:
    • arrhythmias (including Torsades de pointes)
    • tachycardia
    • QTc interval prolongation
    • conduction disorders
    • hypotension
    • shock
    • heart failure
    • cardiac arrest
  • Apnoea
  • Cyanosis
  • Respiratory depression
  • Vomiting
  • Fever
  • Sweating
  • Oliguria
  • Anuria

Шаблон:Div col end

There is no specific antidote for overdose and all treatment is purely supportive and symptomatic.[15] Treatment with activated charcoal may be used to limit absorption in cases of oral overdose.[15] Anyone suspected of overdosing on clomipramine should be hospitalised and kept under close surveillance for at least 72 hours.[15] Clomipramine has been reported as being less toxic in overdose than most other TCAs in one meta-analysis but this may well be due to the circumstances surrounding most overdoses as clomipramine is more frequently used to treat conditions for which the rate of suicide is not particularly high such as OCD.[81] In another meta-analysis, however, clomipramine was associated with a significant degree of toxicity in overdose.[82]

Interactions

Clomipramine may interact with a number of different medications, including the monoamine oxidase inhibitors which include isocarboxazid, moclobemide, phenelzine, selegiline and tranylcypromine, antiarrhythmic agents (due to the effects of TCAs like clomipramine on cardiac conduction. There is also a potential pharmacokinetic interaction with quinidine due to the fact that clomipramine is metabolised by CYP2D6 in vivo), diuretics (due to the potential for hypokalaemia (low blood potassium) to develop which increases the risk for QT interval prolongation and torsades de pointes), the selective serotonin reuptake inhibitors (SSRIs; due to both potential additive serotonergic effects leading to serotonin syndrome and the potential for a pharmacokinetic interaction with the SSRIs that inhibit CYP2D6 (e.g., fluoxetine, paroxetine) and serotonergic agents such as triptans, other tricyclic antidepressants, tramadol, etc. (due to the potential for serotonin syndrome).[15] Its use is also advised against in those concurrently on CYP2D6 inhibitors, due to the potential for increased plasma levels of clomipramine and the resulting potential for CNS and cardiotoxicity.[15]

Fluvoxamine increases the serotoninergic effects of clomipramine and, likewise, clomipramine increases fluvoxamine levels.[83]

Pharmacology

Pharmacodynamics

Шаблон:See also

Clomipramine (and metabolite)[84]
Site Шаблон:Abbr Шаблон:Abbrlink Species Ref
Шаблон:Abbrlink 0.14–0.28 40 Human/rat [85][86][87]
Шаблон:Abbrlink 38–53.7 0.32 Human/rat [85][86][87]
Шаблон:Abbrlink ≥2,190 2,100 Human/rat [85][86][87]
5-HT1A ≥7,000 19,000 Human/Шаблон:Abbr [88][86][87]
5-HT1B >10,000 Шаблон:Abbr Human [86]
5-HT1D >10,000 Шаблон:Abbr Human [86]
5-HT2A 27–35.5 130 Human/Шаблон:Abbr [88][86][87]
5-HT2B Шаблон:Abbr Шаблон:Abbr Шаблон:Abbr Шаблон:Abbr
5-HT2C 64.6 Шаблон:Abbr Human [86]
5-HT3 460–985 Шаблон:Abbr Rodent [86][89][90]
5-HT6 53.8 Шаблон:Abbr Rat [91]
5-HT7 127 Шаблон:Abbr Rat [92]
α1 3.2–38 190 Human/Шаблон:Abbr [86][93][87]
α2 525–3,200 1,800 Human/Шаблон:Abbr [86][93][87]
β 22,000 16,000 Undefined [87]
D1 219 320 Human/Шаблон:Abbr [89][87]
D2 77.6–190 1,200 Human/Шаблон:Abbr [86][93][87]
D3 30–50.1 Шаблон:Abbr Human [86][89]
D4 Шаблон:Abbr Шаблон:Abbr Шаблон:Abbr Шаблон:Abbr
D5 Шаблон:Abbr Шаблон:Abbr Шаблон:Abbr Шаблон:Abbr
H1 13–31 450 Human/Шаблон:Abbr [94][93][87]
H2 209 Шаблон:Abbr Human [94]
H3 9,770 Шаблон:Abbr Human [94]
H4 5,750 Шаблон:Abbr Human [94]
Шаблон:Abbrlink 37 92 Human/Шаблон:Abbr [93][87]
σ1 546 Шаблон:Abbr Rat [95]
Шаблон:Abbrlink 130 (Шаблон:Abbrlink) Шаблон:Abbr Human [96]
Values are Ki (nM), unless otherwise noted. The smaller the value, the more strongly the drug binds to the site.

Clomipramine is a reuptake inhibitor of serotonin and norepinephrine, or a serotonin–norepinephrine reuptake inhibitor (SNRI); that is, it blocks the reuptake of these neurotransmitters back into neurons by preventing them from interacting with their transporters, thereby increasing their extracellular concentrations in the synaptic cleft and resulting in increased serotonergic and noradrenergic neurotransmission.[97][85] In addition, clomipramine also has antiadrenergic, antihistamine, antiserotonergic, antidopaminergic, and anticholinergic activities. It is specifically an antagonist of the α1-adrenergic receptor, the histamine H1 receptor, the serotonin 5-HT2A, 5-HT2C, 5-HT3, 5-HT6, and 5-HT7 receptors, the dopamine D1, D2, and D3 receptors, and the muscarinic acetylcholine receptors (M1–M5).[93][86] Like other TCAs, clomipramine weakly blocks voltage-dependent sodium channels as well.[97][11][98]

Probably all “anticholinergic” side-effects may be successfully reversed in a majority of people with bethanechol chloride,[99][100][101] although knowledge of this amenability has unfortunately decreased in medical circles over the decades. It (bethanechol supplementation) arguably should, however, be seriously entertained when tricyclics which often carry significant anti-muscarinic effects (amitriptyline, protriptyline, imipramine, clomipramine) are prescribed, as it may alleviate potentially otherwise-limiting side-effects (blurry vision, dry mouth, urinary hesitancy/retention, etc.). This practice can make drugs of otherwise indispensably potent value more tolerable to certain patients and spare them needless suffering, hence-reducing the overall side-effect burden or concern thereof.

Although clomipramine shows around 100- to 200-fold preference in affinity for the serotonin transporter (SERT) over the norepinephrine transporter (NET), its major active metabolite, desmethylclomipramine (norclomipramine), binds to the NET with very high affinity (Ki = 0.32 nM) and with dramatically reduced affinity for the SERT (Ki = 31.6 nM).[102][103] Moreover, desmethylclomipramine circulates at concentrations that are approximately twice those of clomipramine.[104] In accordance, occupancy of both the SERT and the NET has been shown with clomipramine administration in positron emission tomography studies with humans and non-human primates.[105][106] As such, clomipramine is in fact a fairly balanced SNRI rather than only a serotonin reuptake inhibitor (SRI).[107]

The antidepressant effects of clomipramine are thought to be due to reuptake inhibition of serotonin and norepinephrine,[97] while serotonin reuptake inhibition only is thought to be responsible for the effectiveness of clomipramine in the treatment of OCD. Conversely, antagonism of the H1, α1-adrenergic, and muscarinic acetylcholine receptors is thought to contribute to its side effects.[97] Blockade of the H1 receptor is specifically responsible for the antihistamine effects of clomipramine and side effects like sedation and somnolence (sleepiness).[97] Antagonism of the α1-adrenergic receptor is thought to cause orthostatic hypotension and dizziness.[97] Inhibition of muscarinic acetylcholine receptors is responsible for the anticholinergic side effects of clomipramine like dry mouth, constipation, urinary retention, blurred vision, and cognitive/memory impairment.[97] In overdose, sodium channel blockade in the brain is believed to cause the coma and seizures associated with TCAs while blockade of sodium channels in the heart is considered to cause cardiac arrhythmias, cardiac arrest, and death.[97][11] On the other hand, sodium channel blockade is also thought to contribute to the analgesic effects of TCAs, for instance in the treatment of neuropathic pain.[108]

The exceptionally strong serotonin reuptake inhibition of clomipramine likely precludes the possibility of its antagonism of serotonin receptors (which it binds to with more than 100-fold lower affinity than the SERT) resulting in a net decrease in signaling by these receptors. In accordance, while serotonin receptor antagonists like cyproheptadine and chlorpromazine are effective as antidotes against serotonin syndrome,[109][110] clomipramine is nonetheless capable of inducing this syndrome.[107] In fact, while all TCAs are SRIs and serotonin receptor antagonists to varying extents, the only TCAs that are associated with serotonin syndrome are clomipramine and to a lesser extent its dechlorinated analogue imipramine,[107][109] which are the two most potent SRIs of the TCAs (and in relation to this have the highest ratios of serotonin reuptake inhibition to serotonin receptor antagonism).[111] As such, whereas other TCAs can be combined with monoamine oxidase inhibitors (with caution due to the risk of hypertensive crisis from NET inhibition; sometimes done in treatment-resistant depressives), clomipramine cannot be due to the risk of serotonin syndrome and death.[97] Unlike the case of its serotonin receptor antagonism, orthostatic hypotension is a common side effect of clomipramine, suggesting that its blockade of the α1-adrenergic receptor is strong enough to overcome the stimulatory effects on the α1-adrenergic receptor of its NET inhibition.[11][97]

Serotonergic activity


Comparison of SERT-active antidepressants[111]
Medication Шаблон:Abbrlink Шаблон:Abbrlink Dosage
(mg/day)		 Шаблон:Abbrlink (Шаблон:Abbr)
(hours)		 Шаблон:Abbr
(ng/mL)		 Шаблон:Abbr / SERT
ratio
Amitriptyline 4.3 34.5 100–200 16 (30) 100–250 23–58
Amoxapine 58.5 16.1 200–300 8 (30) 200–500 3.4–8.5
Butriptyline[85] 1,360 5,100 ? ? ? ?
Clomipramine 0.14–0.28 37 100–200 32 (70) 150–500 536–3,570
Desipramine 17.5 0.8 100–200 30 125–300 7.1–17
Dosulepin[112][113][114] 8.3 45.5 150–225 25 (34) 50–200 6.0–24
Doxepin 66.7 29.4 100–200 18 (30) 150–250 2.2–3.7
Imipramine 1.4 37 100–200 12 (30) 175–300 125–214
Iprindole[85] 1,620 1,262 ? ? ? ?
Lofepramine[85] 70.0 5.4 ? ? ? ?
Nortriptyline 18.5 4.4 75–150 31 60–150 3.2–8.1
Protriptyline 19.6 1.4 15–40 80 100–250 5.1–13
Trimipramine[85] 149 2,450 75–200 16 (30) 100–300 0.67–2.0
Citalopram 1.4 5,100 20–40 36 75–150 54–107
Escitalopram 1.1 7,840 10–20 30 40–80 36–73
Fluoxetine 0.8 244 20–40 53 (240) 100–500 125–625
Fluvoxamine 2.2 1,300 100–200 18 100–200 45–91
Paroxetine 0.34 40 20–40 17 30–100 300–1,000
Sertraline 0.4 417 100–150 23 (66) 25–50 83–167
Duloxetine 1.6 11.2 80–100 11 ? ?
Milnacipran 123 200 ? ? ? ?
Venlafaxine 9.1 535 75–225 5 (11) ? ?
The values for the SERT and NET are Ki (nM). Note that in the Cp / SERT ratio,
free versus protein-bound drug concentrations are not accounted for.

Шаблон:Abbr occupancy by SRIs at clinically approved dosages
Medication Dosage range
(mg/day)[115]		 ~80% Шаблон:Abbr
occupancy
(mg/day)[116][117]		 Ratio (dosage /
80% occupancy)
Citalopram 20–40 40 0.5–1
Escitalopram 10–20 10 1–2
Fluoxetine 20–80 20 1–4
Fluvoxamine 50–300 70 0.71–5
Paroxetine 10–60 20 0.5–3
Sertraline 25–200 50 0.5–4
Duloxetine 20–60 30 0.67–2
Venlafaxine 75–375 75 1–5
Clomipramine 50–250 10 5–25

Clomipramine is an extremely strong SRI by all accounts.[118][119] Its affinity for the SERT was reported in one study using human tissues to be 0.14 nM, which is considerably higher than that of other TCAs.[86][111] For example, the TCAs with the next highest affinities for the SERT in the study were imipramine, amitriptyline, and dosulepin (dothiepin), with Ki values of 1.4 nM, 4.3 nM, and 8.3 nM, respectively.[111] In addition, clomipramine has a terminal half-life that is around twice as long as that of amitriptyline and imipramine.[111][120] In spite of these differences however, clomipramine is used clinically at the same usual dosages as other serotonergic TCAs (100–200 mg/day).[111]Some health authorities recommend daily dosage is in the range of 30 to 75 mg in single or divided doses. Initial dosage should be 10 mg/day with gradual increments to 30-150 mg/day in divided doses or as a single dose at bedtime. Health Canada recommends maximum dose for outpatients is preferred at 200 mg/day.[121] Sustained-release 75 mg formulation may be preferable at doses above 150mg/day (i.e 200mg to 250mg/day).[122][123] It achieves typical circulating concentrations that are similar in range to those of other TCAs but with an upper limit that is around twice that of amitriptyline and imipramine.[111] For these reasons, clomipramine is the most potent SRI among the TCAs and is far stronger as an SRI than other TCAs at typical clinical dosages.[118][119] In addition, clomipramine is more potent as an SRI than any selective serotonin reuptake inhibitors (SSRIs); it is more potent than paroxetine, which is the strongest SSRI.[111]

A positron emission tomography study found that a single low dose of 10 mg clomipramine to healthy volunteers resulted in 81.1% occupancy of the SERT, which was comparable to the 84.9% SERT occupancy by 50 mg fluvoxamine.[105] In the study, single doses of 5 to 50 mg clomipramine resulted in 67.2 to 94.0% SERT occupancy while single doses of 12.5 to 50 mg fluvoxamine resulted in 28.4 to 84.9% SERT occupancy.[105] Chronic treatment with higher doses was able to achieve up to 100.0% SERT occupancy with clomipramine and up to 93.6% SERT occupancy with fluvoxamine.[105] Other studies have found 83% SERT occupancy with 20 mg/day paroxetine and 77% SERT occupancy with 20 mg/day citalopram.[105][124] These results indicate that very low doses of clomipramine are able to substantially occupy the SERT and that clomipramine achieves higher occupancy of the SERT than SSRIs at comparable doses.[105][116] Moreover, clomipramine may be able to achieve more complete occupancy of the SERT at high doses, at least relative to fluvoxamine.[105]

If the ratios of the 80% SERT occupancy dosage and the approved clinical dosage range are calculated and compared for SSRIs, SNRIs, and clomipramine, it can be deduced that clomipramine is by far the strongest SRI used medically.[116][115] The lowest approved dosage of clomipramine can be estimated to be roughly comparable in SERT occupancy to the maximum approved dosages of the strongest SSRIs and SNRIs.[116][115] Because their mechanism of action was originally not known and dose-ranging studies were never conducted, first-generation antipsychotics were dramatically overdosed in patients.[116] It has been suggested that the same may have been true for clomipramine and other TCAs.[116] Nonetheless, there is little doubt that many may, indeed, benefit from much higher doses. 250 mg/d, as mentioned elsewhere, is the typical maximum recommended dose but some people may need as much as 300 mg/d or more to benefit from all clomipramine has to offer beyond its potent SNRI capacity alone.[125]

Obsessive–compulsive disorder

Clomipramine was the first drug that was investigated for and found to be effective in the treatment of OCD.[11][126] In addition, it was the first drug to be approved by the Шаблон:Abbrlink in the United States for the treatment of OCD.[127] The effectiveness of clomipramine in the treatment of OCD is far greater than that of other TCAs, which are comparatively weak SRIs; a meta-analysis found pre- versus post-treatment effect sizes of 1.55 for clomipramine relative to a range of 0.67 for imipramine and 0.11 for desipramine.[128] In contrast to other TCAs, studies have found that clomipramine and SSRIs, which are more selective SRIs, have similar effectiveness in the treatment of OCD.[128] However, multiple meta-analyses have found that clomipramine nonetheless retains a significant effectiveness advantage relative to SSRIs;[129] in the same meta-analysis mentioned previously, the effect sizes of SSRIs in the treatment of OCD ranged from 0.81 for fluoxetine to 1.36 for sertraline (relative to 1.55 for clomipramine).[128] However, the effectiveness advantage for clomipramine has not been apparent in head-to-head comparisons of clomipramine versus SSRIs for OCD.[129] The differences in effectiveness findings could be due to differences in methodologies across non-head-to-head studies.[128][129]

Relatively high doses of SSRIs are needed for effectiveness in the treatment of OCD.[130] Studies have found that high dosages of SSRIs above the normally recommended maximums are significantly more effective in OCD treatment than lower dosages (e.g., 250 to 400 mg/day sertraline versus 200 mg/day sertraline).[130][131] In addition, the combination of clomipramine and SSRIs has also been found to be significantly more effective in alleviating OCD symptoms, and clomipramine is commonly used to augment SSRIs for this reason.[130][127] Studies have found that intravenous clomipramine, which is associated with very high circulating concentrations of the drug and a much higher ratio of clomipramine to its metabolite desmethylclomipramine, is more effective than oral clomipramine in the treatment of OCD.[130][11][127] There is a case report of complete remission from OCD for approximately one month following a massive overdose of fluoxetine, an SSRI with a uniquely long duration of action.[132] Taken together, stronger serotonin reuptake inhibition has consistently been associated with greater alleviation of OCD symptoms, and since clomipramine, at the clinical dosages in which it is employed, is effectively the strongest SRI used medically (see table above), this may underlie its unique effectiveness in the treatment of OCD.

In addition to serotonin reuptake inhibition, clomipramine is also a mild but clinically significant antagonist of the dopamine D1, D2, and D3 receptors at high concentrations.[111][129][133] Addition of antipsychotics, which are potent dopamine receptor antagonists, to SSRIs, has been found to significantly augment their effectiveness in the treatment of OCD.[129][134] As such, besides strong serotonin reuptake inhibition, clomipramine at high doses might also block dopamine receptors to treat OCD symptoms, and this could additionally or alternatively be involved in its possible effectiveness advantage over SSRIs.[135][136] For this reason, it may also be that augmentation with neuroleptics (a common procedure in the occurrence of inadequate response to monotherapy with an SRI) is needed with less frequency with clomipramine relative to SSRIs, the latter of-which apparently lack significant activity as dopamine-receptor antagonists.

Although clomipramine is probably more effective in the treatment of OCD compared to SSRIs, it is greatly inferior to them in terms of tolerability and safety due to its lack of selectivity for the SERT and promiscuous pharmacological activity.[129][137] In addition, clomipramine has high toxicity in overdose and can potentially result in death, whereas death rarely, if ever, occurs with overdose of SSRIs.[129][137] It is for these reasons that clomipramine, in spite of potentially superior effectiveness to SSRIs, is now rarely used as a first-line agent in the treatment of OCD, with SSRIs being used as first-line therapies instead and clomipramine generally being reserved for more severe cases and as a second-line agent.[137]

Pharmacokinetics

The oral bioavailability of clomipramine is approximately 50%.[13] Peak plasma concentrations occur around 2–6 hours (with an average of 4.7 hours) after taking clomipramine orally and are in the range of 56–154 ng/mL (178–489 nmol/L).[13] Steady-state concentrations of clomipramine are around 134–532 ng/mL (426–1,690 nmol/L), with an average of 218 ng/mL (692 nmol/L), and are reached after 7 to 14 days of repeated dosing.[13] Steady-state concentrations of the active metabolite, desmethylclomipramine, are around 230–550 ng/mL (730–1,750 nmol/L).[13] The volume of distribution (Vd) of clomipramine is approximately 17 L/kg.[14] It binds approximately 97–98% to plasma proteins,[13][14] primarily to albumin.[13] Clomipramine is metabolized in the liver mainly by CYP2D6.[14] It has a terminal half-life of 32 hours,[138][139] and its N-desmethyl metabolite, desmethylclomipramine, has a terminal half-life of approximately 69 hours.[14] Clomipramine is mostly excreted in urine (60%) and feces (32%).[14]

Although the normal maximum-recommended total daily dosage of clomipramine is 250 milligrams, treatment-resistant cases of depression[140] and obsessive-compulsive disorder may require corresponding doses within the range of 255 to 300 milligrams. Indeed, doses of 375 milligrams per day, sometimes in combination with venlafaxine[141] or aripiprazole, have not only been necessary but, remarkably, relatively well-tolerated. Caution, however, is generally prudent when doing this, as seizures, which are more likely to occur with clomipramine than every other tricyclic antidepressant besides maprotiline, become more and more of a risk beyond the normally-recommended upper-ceiling. At daily doses ≤ 250 m.g., the incidence of seizures may be reliably estimated to be around the order of 0.48%.[142] (All tricyclic antidepressants technically lower the seizure-threshold but this is only significant with amoxapine, maprotiline and, indeed, clomipramine.[143])

Dose-increases between 25 m.g. and 150 m.g., barring significant drug-drug interactions which may elevate clomipramine blood-levels, should be titrated in doses of 50 m.g. (25 m.g. in the case of panic disorder and 10 to 25 m.g. in the cases of premature ejaculation[144][145]and narcoleptic cataplexy) and above 150 m.g. in 25 m.g. increments. Average optimal total daily doses for depression (whether mild or severe), premature ejaculation, cataplexy-narcolepsy, obsessive-compulsive disorder, panic disorder and trichotilomania respectively are (in milligrams) 150, 50, 25 - 75, 150 - 250, 50 - 150 and 150 - 200. Some consider the minimum optimally-therapeutic dose of clomipramine in obsessive-compulsive disorder, which often requires much higher levels of serotoninergic concentration than other indications for these drugs, to be 200, rather than 150, milligrams per day. For premature ejaculation, clomipramine can be taken prn 3 to 5 hours before attempted sexual intercourse.

Chemistry

Clomipramine is a tricyclic compound, specifically a dibenzazepine, and possesses three rings fused together with a side chain attached in its chemical structure.[146] Other dibenzazepine TCAs include imipramine, desipramine, and trimipramine.[146] Clomipramine is a derivative of imipramine with a chlorine atom added to one of its rings and is also known as 3-chloroimipramine.[147] It is a tertiary amine TCA, with its side chain-demethylated metabolite desmethylclomipramine being a secondary amine.[148][149] Other tertiary amine TCAs include amitriptyline, imipramine, dosulepin (dothiepin), doxepin, and trimipramine.[150][151] The chemical name of clomipramine is 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine and its free base form has a chemical formula of C19H23ClN2 with a molecular weight of 314.857 g/mol.[152] The drug is used commercially almost exclusively as the hydrochloride salt; the free base has been used rarely.[152][153] The CAS Registry Number of the free base is 303-49-1 and of the hydrochloride is 17321-77-6.[152][153]

History

Clomipramine was developed by Geigy as a chlorinated derivative of imipramine.[11][154] It was first referenced in the literature in 1961 and was patented in 1963.[154] The drug was first approved for medical use in Europe in the treatment of depression in 1970,[154] and was the last of the major TCAs to be marketed.[155] In fact, clomipramine was initially considered to be a "me-too drug" by the FDA, and in relation to this, was declined licensing for depression in the United States.[155] As such, to this day, clomipramine remains the only TCA that is available in the United States that is not approved for the treatment of depression, in spite of the fact that it is a highly effective antidepressant.[156]

Clomipramine was eventually approved in the United States for the treatment of OCD in 1989 and became available in 1990.[127][11] It was the first drug to be investigated and found effective in the treatment of OCD.[11][126] The benefits in OCD were first reported by Juan José López-Ibor in 1967,[157][158] and the first double-blind, placebo-controlled clinical trial of clomipramine for OCD was conducted in 1976,[126] with more rigorous clinical studies that solidified its effectiveness conducted in the 1980s.[11] It remained the "gold standard" for the treatment of OCD for many years until the introduction of the SSRIs, which have since largely superseded it due to greatly improved tolerability and safety (although notably not effectiveness).[159][160] Clomipramine is the only TCA that has been shown to be effective in the treatment of OCD and that is approved by the FDA for the treatment of OCD; the other TCAs failed clinical trials for this indication, likely due to insufficient serotonergic activity.[161][162]

Society and culture

Generic names

Clomipramine is the English and French generic name of the drug and its Шаблон:Abbrlink, Шаблон:Abbrlink, and Шаблон:Abbrlink, while clomipramine hydrochloride is its Шаблон:Abbrlink, Шаблон:Abbrlink, Шаблон:Abbrlink, and Шаблон:Abbrlink.[152][153][163][164] Clomipramina is its generic name in Spanish, Portuguese and Italian and its Шаблон:Abbrlink, while clomipramin is its generic name in German and clomipraminum is its generic name in Latin.[153][164]

Brand names

Clomipramine is marketed throughout the world mainly under the brand names Anafranil and Clomicalm for use in humans and animals, respectively.[153][164]

Veterinary uses

In the U.S., clomipramine is only licensed to treat separation anxiety in dogs for which it is sold under the brand name Clomicalm.[165] It has proven effective in the treatment of obsessive–compulsive disorders in cats and dogs.[166][167] In dogs, it has also demonstrated similar efficacy to fluoxetine in treating tail chasing.[168] In dogs some evidence suggests its efficacy in treating noise phobia.[169]

Clomipramine has also demonstrated efficacy in treating urine spraying in cats.[170] Various studies have been done on the effects of clomipramine on cats to reduce urine spraying/marking behavior. It has been shown to be able to reduce this behavior by up to 75% in a trial period of four weeks.[171]

References

Шаблон:Reflist

Шаблон:Antidepressants Шаблон:Anxiolytics Шаблон:OCD pharmacotherapies Шаблон:Navboxes Шаблон:Tricyclics Шаблон:Portal bar Шаблон:Authority control

Партнерские ресурсы
Криптовалюты
Магазины
Хостинг
Разное

  1. ↑ 1,0 1,1 1,2 1,3 1,4 1,5 1,6 1,7 1,8 1,9 Шаблон:Cite web
  2. ↑ Swedo, S E et al. “A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling).” The New England journal of medicine vol. 321,8 (1989): 497-501. doi:10.1056/NEJM198908243210803
  3. ↑ Adebayo, Kazeem Olaide et al. “Body dysmorphic disorder in a Nigerian boy presenting as depression: a case report and literature review.” International journal of psychiatry in medicine vol. 44,4 (2012): 367-72. doi:10.2190/PM.44.4.f
  4. ↑ Phillips, K.A., Albertini, R.S., Siniscalchi, J.M., Khan, A. and Robinson, M., 2001. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study. Journal of Clinical Psychiatry, 62(9), pp.721-727.
  5. ↑ Pallanti, S. and Koran, L.M., 1996. Intravenous, pulse-loaded clomipramine in body dysmorphic disorder: two case reports. CNS Spectrums, 1(2), pp.54-57.
  6. ↑ Shapiro, W. R. (1975). Treatment of cataplexy with clomipramine. Archives of neurology, 32(10), 653-656.
  7. ↑ Dauvilliers Y, Siegel JM, Lopez R, Torontali ZA, Peever JH. Cataplexy—clinical aspects, pathophysiology and management strategy. Nature Reviews Neurology. 2014 Jul;10(7):386-95..
  8. ↑ Chen C. N. (1980). The use of clomipramine as an REM sleep suppressant in narcolepsy. Postgraduate medical journal, 56 Suppl 1, 86–89.
  9. ↑ Karameh, Wael Karameh, and Munir Khani. “Intravenous Clomipramine for Treatment-Resistant Obsessive-Compulsive Disorder.” The international journal of neuropsychopharmacology vol. 19,2 pyv084. 28 July 2015, doi:10.1093/ijnp/pyv084
  10. ↑ Sallee, F R et al. “Pulse intravenous clomipramine for depressed adolescents: double-blind, controlled trial.” The American journal of psychiatry vol. 154,5 (1997): 668-73. doi:10.1176/ajp.154.5.668
  11. ↑ 11,0 11,1 11,2 11,3 11,4 11,5 11,6 11,7 11,8 11,9 Шаблон:Cite book
  12. ↑ Шаблон:Cite book
  13. ↑ 13,0 13,1 13,2 13,3 13,4 13,5 13,6 13,7 13,8 Шаблон:Cite web
  14. ↑ 14,0 14,1 14,2 14,3 14,4 14,5 14,6 14,7 Шаблон:Cite web
  15. ↑ 15,0 15,1 15,2 15,3 15,4 15,5 15,6 15,7 15,8 15,9 Шаблон:Cite web
  16. ↑ 16,0 16,1 16,2 16,3 16,4 Шаблон:Cite web
  17. ↑ 17,0 17,1 17,2 Шаблон:Cite book
  18. ↑ 18,0 18,1 18,2 18,3 Шаблон:Cite book
  19. ↑ Шаблон:Cite web
  20. ↑ Шаблон:Cite web
  21. ↑ Danish University Antidepressant Group. (1990). Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders, 18(4), 289-299.
  22. ↑ Шаблон:Cite journal
  23. ↑ Gillman, Ken, and Last updated Mar. "Clomipramine: Potent SNRI Anti-Depressant."
  24. ↑ Vestergaard, P., Gram, L. F., Kragh-Sørensen, P., Bech, P., Reisby, N., & Bolwig, T. G. (1993). Therapeutic potentials of recently introduced antidepressants. Danish University Antidepressant Group. Psychopharmacology series, 10, 190–198. https://doi.org/10.1007/978-3-642-78010-3_18
  25. ↑ Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, Lam RW, Lépine JP, Möller HJ, Nutt DJ, Rouillon F. Which antidepressants have demonstrated superior efficacy? A review of the evidence. International clinical psychopharmacology. 2007 Nov 1;22(6):323-9.
  26. ↑ Wijkstra J, Lijmer J, Balk FJ, Geddes JR, Nolen WA. Pharmacological treatment for unipolar psychotic depression: systematic review and meta-analysis. The British Journal of Psychiatry. 2006 May;188(5):410-5.
  27. ↑ Bayes, A. and Parker, G., 2019. How to choose an antidepressant medication. Acta Psychiatrica Scandinavica, 139(3), pp.280-291.
  28. ↑ Anderson, I.M., 2000. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. Journal of affective disorders, 58(1), pp.19-36.
  29. ↑ Шаблон:Cite journal
  30. ↑ Шаблон:Cite journal
  31. ↑ Шаблон:Cite journal
  32. ↑ Шаблон:Cite journal
  33. ↑ Шаблон:Cite journal
  34. ↑ Шаблон:Cite journal
  35. ↑ Шаблон:Cite journal
  36. ↑ Шаблон:Cite journal
  37. ↑ Шаблон:Cite journal
  38. ↑ Шаблон:Cite journal
  39. ↑ Шаблон:Cite journal
  40. ↑ Шаблон:Cite journal
  41. ↑ Шаблон:Cite journal
  42. ↑ Шаблон:Cite journal
  43. ↑ 43,0 43,1 Шаблон:Cite journal
  44. ↑ Шаблон:Cite web
  45. ↑ Шаблон:Cite journal
  46. ↑ Шаблон:Cite journal
  47. ↑ Шаблон:Cite journal
  48. ↑ Шаблон:Cite journal
  49. ↑ Шаблон:Cite journal
  50. ↑ Шаблон:Cite journal
  51. ↑ Шаблон:Cite journal
  52. ↑ Шаблон:Cite journal
  53. ↑ Шаблон:Cite journal
  54. ↑ Шаблон:Cite journal
  55. ↑ Шаблон:Cite journal
  56. ↑ Шаблон:Cite journal
  57. ↑ Шаблон:Cite journal
  58. ↑ Шаблон:Cite journal
  59. ↑ Wilson, M., & Tripp, J. (2022). Clomipramine. In StatPearls. StatPearls Publishing.
  60. ↑ Шаблон:Cite journal
  61. ↑ 61,0 61,1 Шаблон:Cite journal
  62. ↑ Шаблон:Cite journal
  63. ↑ Шаблон:Cite journal
  64. ↑ 64,0 64,1 Шаблон:Cite journal
  65. ↑ Шаблон:Cite journal
  66. ↑ Шаблон:Cite journal
  67. ↑ Шаблон:Cite journal
  68. ↑ Шаблон:Cite journal
  69. ↑ Шаблон:Cite journal
  70. ↑ Шаблон:Cite journal
  71. ↑ Шаблон:Cite journal
  72. ↑ Шаблон:Cite journal
  73. ↑ Шаблон:Cite journal
  74. ↑ Шаблон:Cite journal
  75. ↑ Шаблон:Cite journal
  76. ↑ Шаблон:Cite journal
  77. ↑ Шаблон:Cite journal
  78. ↑ Шаблон:Cite journal
  79. ↑ Шаблон:Cite journal
  80. ↑ Шаблон:Cite journal
  81. ↑ Шаблон:Cite journal
  82. ↑ Шаблон:Cite journal
  83. ↑ Шаблон:Cite journal
  84. ↑ Шаблон:Cite web
  85. ↑ 85,0 85,1 85,2 85,3 85,4 85,5 85,6 85,7 Шаблон:Cite journal
  86. ↑ 86,00 86,01 86,02 86,03 86,04 86,05 86,06 86,07 86,08 86,09 86,10 86,11 86,12 86,13 86,14 Шаблон:Cite journal
  87. ↑ 87,00 87,01 87,02 87,03 87,04 87,05 87,06 87,07 87,08 87,09 87,10 87,11 Шаблон:Cite journal
  88. ↑ 88,0 88,1 Шаблон:Cite journal
  89. ↑ 89,0 89,1 89,2 Шаблон:Cite journal
  90. ↑ Шаблон:Cite journal
  91. ↑ Шаблон:Cite journal
  92. ↑ Шаблон:Cite journal
  93. ↑ 93,0 93,1 93,2 93,3 93,4 93,5 Шаблон:Cite journal
  94. ↑ 94,0 94,1 94,2 94,3 Шаблон:Cite journal
  95. ↑ Шаблон:Cite journal
  96. ↑ Шаблон:Cite journal
  97. ↑ 97,0 97,1 97,2 97,3 97,4 97,5 97,6 97,7 97,8 97,9 Шаблон:Cite book
  98. ↑ Шаблон:Cite book
  99. ↑ Boyson S. J. (1988). Bethanechol for anticholinergic side effects. Annals of neurology, 23(4), 422–423. https://doi.org/10.1002/ana.410230429
  100. ↑ Шаблон:Cite journal
  101. ↑ Шаблон:Cite journal
  102. ↑ Шаблон:Cite book
  103. ↑ Шаблон:Cite book
  104. ↑ Шаблон:Cite book
  105. ↑ 105,0 105,1 105,2 105,3 105,4 105,5 105,6 Шаблон:Cite journal
  106. ↑ Шаблон:Cite journal
  107. ↑ 107,0 107,1 107,2 Шаблон:Cite journal
  108. ↑ Шаблон:Cite book
  109. ↑ 109,0 109,1 Шаблон:Cite journal
  110. ↑ Шаблон:Cite journal
  111. ↑ 111,0 111,1 111,2 111,3 111,4 111,5 111,6 111,7 111,8 Шаблон:Cite book
  112. ↑ Шаблон:Cite book
  113. ↑ Шаблон:Cite book
  114. ↑ Шаблон:Cite book
  115. ↑ 115,0 115,1 115,2 Шаблон:Cite book
  116. ↑ 116,0 116,1 116,2 116,3 116,4 116,5 Шаблон:Cite journal
  117. ↑ Шаблон:Cite journal
  118. ↑ 118,0 118,1 Шаблон:Cite book
  119. ↑ 119,0 119,1 Шаблон:Cite book
  120. ↑ Шаблон:Cite book
  121. ↑ Шаблон:Cite web
  122. ↑ Шаблон:Cite web
  123. ↑ Шаблон:Cite web
  124. ↑ Шаблон:Cite journal
  125. ↑ Ananth, J., 1986. Clomipramine: an antiobsessive drug. The Canadian Journal of Psychiatry, 31(3), pp.253-258.
  126. ↑ 126,0 126,1 126,2 Шаблон:Cite book
  127. ↑ 127,0 127,1 127,2 127,3 Шаблон:Cite book
  128. ↑ 128,0 128,1 128,2 128,3 Шаблон:Cite journal
  129. ↑ 129,0 129,1 129,2 129,3 129,4 129,5 129,6 Шаблон:Cite journal
  130. ↑ 130,0 130,1 130,2 130,3 Шаблон:Cite journal
  131. ↑ Шаблон:Cite journal
  132. ↑ Шаблон:Cite journal
  133. ↑ Шаблон:Cite journal
  134. ↑ Шаблон:Cite journal
  135. ↑ Шаблон:Cite journal
  136. ↑ Шаблон:Cite journal
  137. ↑ 137,0 137,1 137,2 Шаблон:Cite book
  138. ↑ Шаблон:Cite journal
  139. ↑ Шаблон:Cite journal
  140. ↑ Amsterdam, J.D., García‐España, F. and Rosenzweig, M., 1997. Clomipramine augmentation in treatment‐resistant depression. Depression and Anxiety, 5(2), pp.84-90.
  141. ↑ Gomez, J.M. and Perramon, C.T., 2000. Combined treatment with venlafaxine and tricyclic antidepressants in depressed patients who had partial response to clomipramine or imipramine: initial findings. J Clin Psychiatry, 61(4), pp.285-289.
  142. ↑ DeVeaugh-Geiss, J., Landau, P. and Katz, R., 1989. Treatment of obsessive compulsive disorder with clomipramine. Psychiatric Annals, 19(2), pp.97-99.
  143. ↑ Górska, N., Słupski, J., Cubała, W.J., Wiglusz, M.S. and Gałuszko-Węgielnik, M., 2018. Antidepressants in epilepsy. neurologia i neurochirurgia polska, 52(6), pp.657-661.
  144. ↑ Rowland, D.L., De Gouveia Brazao, C.A. and Koos Slob, A., 2001. During the initial titration, it may be necessary to divide the total daily dose up to thrice (to reduce certain side-effects) but once the full optimal dose has been reached, most people can be sustained on a once-at-bedtime dose, or on a prn basis 3 to 5 hours before sexual intercourse in the case of premature ejaculation. Effective daily treatment with clomipramine in men with premature ejaculation when 25 mg (as required) is ineffective. BJU international, 87(4), pp.357-360.
  145. ↑ Mohammed, M.A., CLOMIPRAMINE AS DAILY DOSE IN THE TREATMENT OF PATIENTS WITH PREMATURE.
  146. ↑ 146,0 146,1 Шаблон:Cite book
  147. ↑ Шаблон:Cite book
  148. ↑ Шаблон:Cite book
  149. ↑ Шаблон:Cite book
  150. ↑ Шаблон:Cite book
  151. ↑ Шаблон:Cite book
  152. ↑ 152,0 152,1 152,2 152,3 Шаблон:Cite book
  153. ↑ 153,0 153,1 153,2 153,3 153,4 Шаблон:Cite book
  154. ↑ 154,0 154,1 154,2 Шаблон:Cite journal
  155. ↑ 155,0 155,1 Шаблон:Cite book
  156. ↑ Шаблон:Cite book
  157. ↑ Шаблон:Cite book
  158. ↑ Шаблон:Cite web
  159. ↑ Шаблон:Cite book
  160. ↑ Шаблон:Cite book
  161. ↑ Шаблон:Cite book
  162. ↑ Шаблон:Cite book
  163. ↑ Шаблон:Cite book
  164. ↑ 164,0 164,1 164,2 Шаблон:Cite web
  165. ↑ Шаблон:Cite web
  166. ↑ Шаблон:Cite journal
  167. ↑ Шаблон:Cite journal
  168. ↑ Шаблон:Cite journal
  169. ↑ Шаблон:Cite journal
  170. ↑ Шаблон:Cite journal
  171. ↑ Шаблон:Cite journal
Источник — http://wikihandbk.com/ruwiki/index.php?title=Английская_Википедия:Clomipramine&oldid=13995073